[Radiotherapy and chemotherapy for locally advanced non-small-cell lung cancer: report of a clinical trial and review of the literature. South Osaka Lung Cancer Chemotherapy Study Group].
A prospective nonrandomized phase II trial was performed from June 1989 to Oct 1990 using concurrent chemotherapy and split course radiotherapy in the treatment of inoperable, locally advanced non-small-cell lung cancer (NSCLC). Eligibility criteria consisted of NSCLC, inoperable stage IIIA or IIIB excluding T3N0 or T3N1 of TNM classification, with pleural effusion, age 75 y.o. or less, PS0-2, with measurable lesion, previously untreated, normal bone marrow, adequate renal and hepatic function, PaO2 > or = 70 torr, and with no other active neoplastic disease. Patients were treated with 50 Gy of radiation in 25 fractions to the chest, together with 100 mg/m2 cisplatin and 8 mg/m2 mitomycin-C on day 1 and 29 and vindesine 3 mg/m2 on days 1, 8, 29, 36. Sixty-five patients were entered into this trial and 61 were eligible. There were 4 ineligible patients (1 stage II, 2 stage IV, 1 malignant lymphoma). Fifty-seven patients received 2 or more courses of chemotherapy, with dose modification in 42 patients. Only 5 patients received less than 50 Gy radiation dose. Fifty-three patients had a partial response for an overall response rate of 87% (95% CI 78-95%). Median duration of response was 276 days. Median survival time (MST) was 450 days. One, 2, and 3 year survival were 60%, 37%, and 28%, respectively. In IIIa (13 patients), MST was 358 days and 1, 2, and 3 year survival were 50%, 50%, and 42%, respectively. In IIIB (48%), MST was 450 days and 1, 2, and 3 year survival were 63%, 33%, and 25%, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)